Upper respiratory tract infection mainly characterized by cough
Conditions
Interventions
Sub-topic 1: Montelukast sodium group:Oral administration of montelukast sodium, 10mg/tablet, 1 tablet each time, before bedtimeadministration of montelukast sodium, 10mg/tablet, 1 tablet each time, b
Sub-topic 1: Zhike Shuangjie powder group:Oral Zhike Shuangjie powder, one dose per day, twice a day, after meals
Sub-topic 1: Transdermal administration group:Using Wensan tincture and transdermal medication therapy device, once a day for 45 minutes each time
Sub-topic 2: Montelukast sodium group:Oral administration of montelukast sodium, 10mg/tablet, 1 tablet each time, before bedtimeadministration of montelukast sodium, 10mg/tablet, 1 tablet each time, b
Sub-topic 2: Zhike Baidu powder group:Oral Zhike Baidu powder, one dose per day, twice a day, after meals
Sub-topic 2: Transdermal administration group:Using Wensan tincture and transdermal medication therapy device, once a day for 45 minutes each time
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age = 18, regardless of gender, meets the Western medical diagnostic criteria for upper respiratory tract infections with cough as the main symptom; (2) The diagnostic criteria for traditional Chinese medicine syndrome types are in line with the wind warm attacking lung syndrome; (3) The diagnostic criteria for traditional Chinese medicine syndrome types are in line with the syndrome of wind cold attacking the lungs and Qi deficiency; (4) Voluntarily accept treatment and sign an informed consent form. Sub projects must meet the requirements of (1), (2), and (4) before they can be included in the group; Sub topic 2 can only be included if it meets the requirements of (1), (3), and (4);
Exclusion criteria
Exclusion criteria: (1) If there is any clinically significant abnormality in any laboratory test indicator before screening, and the researcher determines that it is not suitable for inclusion (such as chest X-ray/lung CT indicating lung infection, it is not suitable for inclusion); (2) Merge with other serious primary diseases (malignant tumors, severe liver and kidney dysfunction, severe autoimmune diseases, etc.); (3) Concomitant gastroesophageal reflux disease; (4) Individuals with allergic constitution or allergic to the drugs used in this study; (5) Pregnant, lactating, or intending pregnant women. (6) Patients with mental illness or those without self-awareness; Those who meet any of the above criteria will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough symptom score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual simulation cough symptom score;Cough related quality of life score;Related clinical symptom scores; | — |
Countries
China
Contacts
Public ContactLi Guangxi
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed